Stephanie Fradette

Stories

Biogen's salanersen wins FDA breakthrough status for spinal muscular atrophy

As of June 2026: Leading salanersen's clinical program

Some children with spinal muscular atrophy get a one-time gene therapy, then slowly weaken again. There has been no clear next step for them. On June 4, 2026, the FDA gave Biogen's salanersen a designation meant to speed up that next step.

Updated Jun 4